These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 12231073

  • 1. Insulin resistance as the core defect in type 2 diabetes mellitus.
    Goldstein BJ.
    Am J Cardiol; 2002 Sep 05; 90(5A):3G-10G. PubMed ID: 12231073
    [Abstract] [Full Text] [Related]

  • 2. Insulin resistance, diabetes, and the adipocyte.
    Stolar MW.
    Am J Health Syst Pharm; 2002 Dec 01; 59 Suppl 9():S3-8. PubMed ID: 12489380
    [Abstract] [Full Text] [Related]

  • 3. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones.
    Arner P.
    Trends Endocrinol Metab; 2003 Apr 01; 14(3):137-45. PubMed ID: 12670740
    [Abstract] [Full Text] [Related]

  • 4. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion.
    Groop L.
    Int J Clin Pract Suppl; 2000 Oct 01; (113):3-13. PubMed ID: 11965829
    [Abstract] [Full Text] [Related]

  • 5. [From obesity to diabetes].
    Stöckli R, Keller U.
    Ther Umsch; 2002 Aug 01; 59(8):388-92. PubMed ID: 12235730
    [Abstract] [Full Text] [Related]

  • 6. [Obesity--insulin resistance--type 2 diabetes mellitus].
    Małecki MT.
    Kardiol Pol; 2006 Oct 01; 64(10 Suppl 6):S561-6. PubMed ID: 20527377
    [Abstract] [Full Text] [Related]

  • 7. Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
    Szoke E, Gerich JE.
    Compr Ther; 2005 Oct 01; 31(2):106-12. PubMed ID: 15901939
    [Abstract] [Full Text] [Related]

  • 8. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
    Jia DM, Tabaru A, Nakamura H, Fukumitsu KI, Akiyama T, Otsuki M.
    Metabolism; 2000 Sep 01; 49(9):1167-75. PubMed ID: 11016899
    [Abstract] [Full Text] [Related]

  • 9. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
    de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF.
    Diabetes; 2001 Aug 01; 50(8):1863-71. PubMed ID: 11473050
    [Abstract] [Full Text] [Related]

  • 10. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
    Raji A, Plutzky J.
    Curr Cardiol Rep; 2002 Nov 01; 4(6):514-21. PubMed ID: 12379175
    [Abstract] [Full Text] [Related]

  • 11. Current views on the mechanism of action of thiazolidinedione insulin sensitizers.
    Goldstein BJ.
    Diabetes Technol Ther; 1999 Nov 01; 1(3):267-75. PubMed ID: 11475273
    [Abstract] [Full Text] [Related]

  • 12. Glitazones: clinical effects and molecular mechanisms.
    Stumvoll M, Häring HU.
    Ann Med; 2002 Nov 01; 34(3):217-24. PubMed ID: 12173692
    [Abstract] [Full Text] [Related]

  • 13. Thiazolidinediones -- some recent developments.
    Stumvoll M.
    Expert Opin Investig Drugs; 2003 Jul 01; 12(7):1179-87. PubMed ID: 12831352
    [Abstract] [Full Text] [Related]

  • 14. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
    Saraf N, Sharma PK, Mondal SC, Garg VK, Singh AK.
    J Pharm Pharmacol; 2012 Feb 01; 64(2):161-71. PubMed ID: 22221092
    [Abstract] [Full Text] [Related]

  • 15. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.
    Diabetes; 2002 Oct 01; 51(10):2968-74. PubMed ID: 12351435
    [Abstract] [Full Text] [Related]

  • 16. Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes.
    Evans AJ, Krentz AJ.
    Diabetes Obes Metab; 2001 Aug 01; 3(4):219-29. PubMed ID: 11520301
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M, Vantyghem MC, Schoonjans K, Pattou F.
    Ann Endocrinol (Paris); 2002 Dec 01; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.